Hyperprogression (HP) is a recently defined clinical phenomenon in which patients treated with immunotherapy paradoxically exhibit rapid tumor growth. The mechanisms of hyperprogression remain ill-defined, although recent studies in this issue point to a possible role for Fc receptors in this process..
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359946 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-18-3144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy.
NPJ Precis Oncol
January 2025
Clinical Pharmacology and Quantitative Science, Genmab Inc, Princeton, NJ, USA.
Tumor genomic profiling is often limited to one or two timepoints due to the invasiveness of tissue biopsies, but longitudinal profiling may provide deeper clinical insights. Using ctDNA data from IMpower150 study, we examined genetic changes in metastatic non-squamous NSCLC post-first-line immunotherapy. Mutations were most frequently detected in TP53, KRAS, SPTA1, FAT3, and LRP1B at baseline and during treatment.
View Article and Find Full Text PDFHyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature.
Discov Oncol
January 2025
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Article Synopsis
- Monotherapy with anti-PD-1 monoclonal antibodies has been approved for treating advanced non-small cell lung cancer with positive PD-L1 expression, showing better survival rates than chemotherapy.
- Certain patients experience hyperprogressive disease (HPD) despite this treatment, a phenomenon where cancer progresses rapidly, but the reasons and molecular traits behind it remain unclear.
- This study presents two cases of advanced lung adenocarcinoma with HER2 exon 20 insertion that developed HPD after anti-PD-1 treatment, suggesting this mutation could serve as a biomarker for avoiding ineffective immunotherapy in specific patients.
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer.
Sci Rep
December 2024
Department of Laboratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
Endometrial cancer is the most prevalent form of gynecologic malignancy, with a significant surge in incidence among youngsters. Although the advent of the immunotherapy era has profoundly improved patient outcomes, not all patients benefit from immunotherapy; some patients experience hyperprogression while on immunotherapy. Hence, there is a pressing need to further delineate the distinct immune response profiles in patients with endometrial cancer to enhance prognosis prediction and facilitate the prediction of immunotherapeutic responses.
View Article and Find Full Text PDFPseudoprogression in a patient with hepatocellular carcinoma treated with immunotherapy plus bevacizumab.
Rev Esp Enferm Dig
December 2024
Hepatic Oncology, Hospital Nuestra Señora de Valme, Spain.
A 62-year-old male with hepatocellular carcinoma on a healthy liver underwent surgery in April 2022. Five months after, the patient complained of abdominal pain, with an alpha-fetoprotein (AFP) level exceeding 9000 ng/ml, and CT images showed liver metastases and multiple lung metastases, so treatment with immunotherapy atezolizumab plus bevacizumab was started in September 2022. After four cycles, hyperprogression was observed in liver and lung metastases at first CT evaluation.
View Article and Find Full Text PDFPericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma.
Cancer Cell
December 2024
Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China; Innovation Center of the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510275, China. Electronic address:
Article Synopsis
- Hyperprogressive disease can occur in cancer patients on immune checkpoint blockade (ICB) therapy, revealing the complex interactions of immune cells in cancer progression.
- The study found that certain macrophages can present cancer antigens to CD103 cytotoxic T lymphocytes (CTLs), causing these CTLs to stay near tumors and activate inflammatory pathways that promote cancer growth and resistance to treatment.
- Analysis of HCC patients indicated that the accumulation of CD103 CTLs, despite their effector status, correlates with poor treatment outcomes, suggesting that modifying their distribution could improve ICB therapy effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!